Correspondence 0001493152-23-024983 from Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)

Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: July 20, 2023 · CIK: 0001614067 · Accession: 0001493152-23-024983

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272128

Date

July 20, 2023

Author

Chief

Form

CORRESP

Company

Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)

Letter

Aridis Pharmaceuticals, Inc.

University Avenue, Bldg. B

Los Gatos, CA 95032

July 20, 2023

VIA EDGAR

United States Securities

and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Dillon Hagius

Re: Aridis Pharmaceuticals, Inc.

Form S-1

File No. 333-272128

Ladies and Gentlemen:

Aridis Pharmaceuticals, Inc. (the “Company”) hereby respectfully withdraws its request, dated July 17, 2023, that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:15 p.m., Eastern Daylight Time, on Monday, July 17, 2023. The Company intends to submit a revised acceleration request at a later date.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any question with respect to this request.

Thank you,

ARIDIS PHARMACEUTICALS, INC.

By: /s/ Vu Truong

Name: Vu Truong

Title: Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

Aridis
Pharmaceuticals, Inc.

983
University Avenue, Bldg. B

Los
Gatos, CA 95032

July
20, 2023

VIA
EDGAR

United
States Securities

and
Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Dillon Hagius

    Re:
    Aridis
    Pharmaceuticals, Inc.

    Form
    S-1

    File
    No. 333-272128

Ladies
and Gentlemen:

Aridis
Pharmaceuticals, Inc. (the “Company”) hereby respectfully withdraws its request, dated July 17, 2023, that the effective
date of the registration statement referred to above be accelerated so that it will become effective at 5:15 p.m., Eastern Daylight Time,
on Monday, July 17, 2023. The Company intends to submit a revised acceleration request at a later date.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 if there are any question
with respect to this request.

    Thank
    you,

    ARIDIS
    PHARMACEUTICALS, INC.

    By:
    /s/
    Vu Truong

    Name:
    Vu
    Truong

    Title:
    Chief
    Executive Officer

SecProbe.io